MAPT and Alzheimer disease: Given that CVD is present in approximately 50–84% of individuals aged 80–90 + at autopsy [15, 19, 20], and is associated with an increased risk of progression to AD and vascular dementia, even after accounting for levels of Aβ and tau [7, 21–24], it is important to understand how hallmark AD biomarkers relate to cognition in initially CU individuals with concurrent CVD.